Teva Confirms Austedo's Effectiveness For HD Chorea With The 4-week Titration Kit

(RTTNews) - Tuesday, Teva Pharmaceutical Industries Ltd.'s (TEVA) U.S. branch, announced a favorable real-world efficacy, safety, compliance, and satisfaction for Huntington's disease or HD segment of the Phase 4 START study, using Austedo or deutetrabenazine tablets.

HD is a fatal, neurodegenerative disease, that can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body movements known as chorea - a symptom that can have a significant impact on daily activities like eating or talking.

"90% of HD patients experience chorea, so it's important for patients to have a treatment option that not only helps address symptoms but helps provide a positive patient experience," said CMO Eric Hughes of Teva.

The START study, a Phase 4 investigation into real-world treatment, revealed that nearly 80 percent of HD chorea patients achieved optimal dosing within four weeks using the 4-week Titration Kit.

The company stated that these findings are set to be unveiled at the 2024 American Academy of Neurology Annual Meeting.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.